Site Search
410 result(s) found for “ adaptive therapy”
-
New Cell Therapy Takes Advantage of a ‘Natural Killer’
Researchers study the use of natural killer cells instead of T cells in cellular immunotherapy
-
New Combination Therapy Brings Hope to Bladder Cancer Patients
Oncolytic immunotherapy and immune checkpoint inhibitor found to be safe and effective in treating muscle-invasive bladder cancer
-
Proton Therapy at Moffitt: The Expertise Behind the Technology
Moffitt built its proton therapy program years before treating patients, recruiting proton-experienced professionals and developing specialized...
-
Study Looks To Improve TIL Therapy for Advanced Melanoma
TIL therapy can be used to treat advanced melanoma when patients do not respond to standard treatment options
-
21MA014N Immunotherapy: Methods For Inhibiting Resistance to Immune Blockade Inhibitor Therapy
FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICEThe Innovation Dedicated to supporting patients every step of the way, with...
-
Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer: A Multidisciplinary Approach
Bladder preservation therapy is a well-established, evidence-based approach for select patients with muscle-invasive bladder cancer.
-
FDA Approves Targeted Radioligand Therapy for Treatment of Advanced Prostate Cancer
The FDA approval of Pluvicto™ is welcome news and an important medical advancement for patients with progressing metastatic castration-resistant...
-
Gut Microbiome Influences How Lymphoma Patients Respond to CAR T Therapy
Moffitt study finds antibiotic treatment and different types of microorganisms can impact chimeric antigen receptor T-cell therapy outcomes
-
Moffitt Cancer Center Celebrates Opening of Proton Therapy Center at Speros
A ribbon cutting ceremony was held with team members from Moffitt, IBA, along with state and local partners
-
Moffitt Experts Recommend New Guidelines for CAR T-Cell Therapy Trials
Current FDA guidelines may cause promising cancer treatments to be abandoned too soon.